Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Remimazolam Soft Mist Sedation Study
2024-516493-30-01Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remimazolam in anxiety disorder and stress, sponsored by Radboud University Medical Center. Primary endpoint: Maximum decrease in BIS compared with baseline. Started Mar 2025; status: completed.
02
Drugs
remimazolam
03
Conditions
anxiety disorderstress
Beyond the preview
Go deeper on 2024-516493-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516493-30-01.